Huazheng Qu1,2, Shui Sun3. 1. Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021, Shandong, China. 2. Department of Joint Surgery, the Third Hospital of Jinan, Jinan, 250132, China. 3. Department of Joint Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China. shuisunsdph@126.com.
Abstract
BACKGROUND: Mesenchymal stromal cells (MSCs) are used as an emerging new option for the treatment of knee osteoarthritis (OA). However, their efficacy remains controversial across studies with different doses of MSCs and cell processing methods. We conducted this meta-analysis to assess the efficacy of MSCs in the treatment of knee OA. METHODS: Randomized controlled trials (RCTs) published in PubMed, Embase, Web of Science, SinoMed (Chinese BioMedical Literature Service System, China), and CNKI (National Knowledge Infrastructure, China) databases were systematically reviewed. The pain level and function improvements were evaluated using visual analog scale (VAS), McMaster Universities Osteoarthritis Index (WOMAC), and International Knee Documentation Committee (IKDC). The pooled estimate was calculated with weighted mean difference (WMD) with 95% confidence intervals (95%CIs). RESULTS: Nine RCTs involving 476 patients were included in this meta-analysis. The pooled estimate showed that the treatment of MSCs significantly reduced VAS, WOMAC pain, WOMAC stiffness, and WOMAC function scores at a long-term follow-up (12 or 24 months). However, for the IKDC and WOMAC total scores, MSCs also showed significant improvement in these outcomes, although this was not statistically significant when compared to the control. CONCLUSION: Based on the current studies, our results suggested that MSCs were a promising option for the treatment of patients with knee OA. However, considering the potential limitations, more well-performed, large-scale RCTs are needed to verify our findings.
BACKGROUND: Mesenchymal stromal cells (MSCs) are used as an emerging new option for the treatment of knee osteoarthritis (OA). However, their efficacy remains controversial across studies with different doses of MSCs and cell processing methods. We conducted this meta-analysis to assess the efficacy of MSCs in the treatment of knee OA. METHODS: Randomized controlled trials (RCTs) published in PubMed, Embase, Web of Science, SinoMed (Chinese BioMedical Literature Service System, China), and CNKI (National Knowledge Infrastructure, China) databases were systematically reviewed. The pain level and function improvements were evaluated using visual analog scale (VAS), McMaster Universities Osteoarthritis Index (WOMAC), and International Knee Documentation Committee (IKDC). The pooled estimate was calculated with weighted mean difference (WMD) with 95% confidence intervals (95%CIs). RESULTS: Nine RCTs involving 476 patients were included in this meta-analysis. The pooled estimate showed that the treatment of MSCs significantly reduced VAS, WOMACpain, WOMAC stiffness, and WOMAC function scores at a long-term follow-up (12 or 24 months). However, for the IKDC and WOMAC total scores, MSCs also showed significant improvement in these outcomes, although this was not statistically significant when compared to the control. CONCLUSION: Based on the current studies, our results suggested that MSCs were a promising option for the treatment of patients with knee OA. However, considering the potential limitations, more well-performed, large-scale RCTs are needed to verify our findings.
Authors: Marc C Hochberg; Roy D Altman; Karine Toupin April; Maria Benkhalti; Gordon Guyatt; Jessie McGowan; Tanveer Towheed; Vivian Welch; George Wells; Peter Tugwell Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794
Authors: Hossein Nejadnik; James H Hui; Erica Pei Feng Choong; Bee-Choo Tai; Eng Hin Lee Journal: Am J Sports Med Date: 2010-04-14 Impact factor: 6.202
Authors: Yang Song; Hui Du; Chengxiang Dai; Li Zhang; Suke Li; David J Hunter; Liangjing Lu; Chunde Bao Journal: Regen Med Date: 2018-02-08 Impact factor: 3.806
Authors: Gerben M van Buul; Michiel Siebelt; Maarten J C Leijs; Pieter Koen Bos; Jan H Waarsing; Nicole Kops; Harrie Weinans; Jan A N Verhaar; Monique R Bernsen; Gerjo J V M van Osch Journal: J Orthop Res Date: 2014-05-16 Impact factor: 3.494
Authors: José M Lamo-Espinosa; Gonzalo Mora; Juan F Blanco; Froilán Granero-Moltó; Jorge M Nuñez-Córdoba; Carmen Sánchez-Echenique; José M Bondía; Jesús Dámaso Aquerreta; Enrique J Andreu; Enrique Ornilla; Eva M Villarón; Andrés Valentí-Azcárate; Fermín Sánchez-Guijo; María Consuelo Del Cañizo; Juan Ramón Valentí-Nin; Felipe Prósper Journal: J Transl Med Date: 2016-08-26 Impact factor: 5.531
Authors: Christoph Schmitz; Christopher Alt; David A Pearce; John P Furia; Nicola Maffulli; Eckhard U Alt Journal: Cells Date: 2022-03-11 Impact factor: 6.600